Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations

Diabetologia

Volumn 57, Issue 11, 2014, Pages 2237-2250

  Patorno, Elisabetta ^a   Patrick, Amanda R ^a   Garry, Elizabeth M ^a   Schneeweiss, Sebastian ^a   Gillet, Victoria G ^a   Bartels, Dorothee B ^b,c   Masso Gonzalez, Elvira ^b   Seeger, John D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cardiovascular outcomes; Epidemiological methods; Glucose lowering medications; Observational studies; Review

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

CARDIOVASCULAR DISEASE; DATA BASE; DIABETES MELLITUS; HUMAN; METHODOLOGY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROPENSITY SCORE; PUBLICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; STUDY DESIGN; TREATMENT DURATION; CARDIOVASCULAR DISEASES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; THEORETICAL MODEL;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, THEORETICAL; RISK FACTORS;

EID: 84919950480     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3364-z     Document Type: Review

References (132)

1. Arana A, Rivero E, Egberts TCG (2004) What do we show and who does so? An analysis of the abstracts presented at the 19th ICPE. Pharmacoepidemiol Drug Saf 13:S330–S331
2. Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58:323–337
3. Schneeweiss S (2010) A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 19:858–868
4. Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167:492–499
5. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28:2345–2351
6. Johnson JA, Simpson SH, Toth EL, Majumdar SR (2005) Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 22:497–502
7. Aguilar D, Bozkurt B, Pritchett A, Petersen NJ, Deswal A (2007) The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol 50:32–36
8. Anselmino M, Ohrvik J, Malmberg K, Standl E, Ryden L (2008) Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 29:177–184
9. Khalangot M, Tronko M, Kravchenko V, Kovtun V (2009) Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 86:247–253
10. Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW (2009) Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf 32:675–690
11. Hsiao FY, Tsai YW, Wen YW et al (2010) Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan. Pharmacoepidemiol Drug Saf 19:786–791
12. Corrao G, Romio SA, Zambon A, Merlino L, Bosi E, Scavini M (2011) Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy. Eur J Clin Pharmacol 67:289–299
13. Loebstein R, Dushinat M, Vesterman-Landes J et al (2011) Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes. J Clin Pharmacol 51:173–180
14. Yeh HT, Hsieh CF, Tsai YW, Huang WF (2012) Effects of thiazolidinediones on cardiovascular events in patients with type 2 diabetes mellitus after drug-eluting stent implantation: a retrospective cohort study using the national health insurance database in Taiwan. Clin Ther 34:885–893
15. Chao TF, Leu HB, Huang CC et al (2012) Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Int J Cardiol 156:199–202
16. Olsson J, Lindberg G, Gottsater M et al (2000) Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43:558–560
17. Johnson JA, Majumdar SR, Simpson SH, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244–2248
18. Evans JM, Doney AS, AlZadjali MA et al (2010) Effect of metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol 106:1006–1010
19. Gamble JM, Simpson SH, Eurich DT, Majumdar SR, Johnson JA (2010) Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 12:47–53
20. Chou CC, Chen WL, Kao TW, Chang YW, Loh CH, Wang CC (2011) Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. Clin Ther 33:1904–1913
21. Maru S, Koch GG, Stender M et al (2005) Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care 28:20–26
22. Engel-Nitz NM, Martin S, Sun P, Buesching D, Fonseca V (2008) Cardiovascular events and insulin therapy: a retrospective cohort analysis. Diabetes Res Clin Pract 81:97–104
23. Toprani A, Fonseca V (2011) Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes. Diabetes Obes Metab 13:276–280
24. Choy-Shan A, Zinn A, Shah B et al (2012) Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease. Coron Artery Dis 23:354–358
25. Margolis DJ, Hoffstad O, Strom BL (2008) Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 17:753–759
26. Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB (2005) The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 21:51–57
27. Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT (2004) Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther 26:1400–1410
28. Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM (2005) Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 22:986–993
29. Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S (2007) A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 16:1065–1071
30. Rhoads GG, Kosiborod M, Nesto RW et al (2009) Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. Am J Cardiol 104:910–916
31. Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ (2012) What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 97:4605–4612
32. Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K (2009) The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Clin Ther 31:2665–2677
33. Koro CE, Bowlin SJ, Weiss SR (2005) Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. Pharmacoepidemiol Drug Saf 14:697–703
34. Horsdal HT, Sondergaard F, Johnsen SP, Rungby J (2011) Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study. Pharmacoepidemiol Drug Saf 20:331–337
35. Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL (2010) Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes 3:538–545
36. Kress S, Kostev K, Dippel FW, Giani G, Rathmann W (2012) Micro- and macrovascular outcomes in type 2 diabetic patients treated with insulin glulisine or human regular insulin: a retrospective database analysis. Int J Clin Pharmacol Ther 50:821–829
37. McAlister FA, Eurich DT, Majumdar SR, Johnson JA (2008) The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 10:703–708
38. Marceille JR, Goins JA, Soni R, Biery JC, Lee TA (2004) Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. Pharmacotherapy 24:1317–1322
39. Rothman KJ, Greenland S (1998) Modern epidemiology, 2nd edn. Lippincott-Raven, Philadelphia
40. Schisterman EF, Cole SR, Platt RW (2009) Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20:488–495
41. Greenland S (2003) Quantifying biases in causal models: classical confounding vs collider-stratification bias. Epidemiology 14:300–306
42. Hartung DM, Touchette DR, Bultemeier NC, Haxby DG (2005) Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a Medicaid claims-based case-control study. Pharmacotherapy 25:1329–1336
43. Johnsen SP, Monster TB, Olsen ML et al (2006) Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 13:134–140
44. Sauer WH, Cappola AR, Berlin JA, Kimmel SE (2006) Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. Am J Cardiol 97:651–654
45. Koro CE, Fu Q, Stender M (2008) An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. Pharmacoepidemiol Drug Saf 17:989–996
46. Dore DD, Trivedi AN, Mor V, Lapane KL (2009) Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction. Pharmacotherapy 29:775–783
47. Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM (2009) Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PLoS One 4:e6080
48. MacDonald MR, Eurich DT, Majumdar SR et al (2010) Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 33:1213–1218
49. Azoulay L, Schneider-Lindner V, Dell'aniello S, Filion KB, Suissa S (2010) Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study. Pharmacoepidemiol Drug Saf 19:343–350
50. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884
51. Evans J, Ogston S, Emslie-Smith A, Morris A (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936
52. Kapinya K, Nijjar PS, Stanek M, Amanullah A (2008) Insulin-sensitizing antihyperglycaemic medications are associated with better outcome in patients with diabetes undergoing cardiac stress testing. Int Med J 38:259–264
53. Pantalone KM, Kattan MW, Yu C et al (2009) The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 46:145–154
54. Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95:1797–1800
55. Adami HO, McLaughlin J, Ekbom A et al (1991) Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2:307–314
56. Johnson E, Bartman B, Briesacher B et al (2013) The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf 22:1–6
57. Ray W (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915–920
58. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM (2007) Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 16:711–725
59. Walker AM, Koro CE, Landon J (2008) Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf 17:760–768
60. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH (2008) Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 168:2368–2375
61. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM (2009) Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 339:b2942
62. Juhaeri J, Gao S, Dai WS (2009) Incidence rates of heart failure, stroke, and acute myocardial infarction among type 2 diabetic patients using insulin glargine and other insulin. Pharmacoepidemiol Drug Saf 18:497–503
63. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304:411–418
64. Best JH, Hoogwerf BJ, Herman WH et al (2011) Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34:90–95
65. Roumie CL, Hung AM, Greevy RA et al (2012) Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 157:601–610
66. Solomon DH, Glynn RJ, Rothman KJ et al (2008) Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 59:1097–1104
67. Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. IARC Sci Publ 87:1–406
68. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS (2003) Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 26:2983–2989
69. Habib ZA, Tzogias L, Havstad SL et al (2009) Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf 18:437–447
70. Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD (2007) The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf 16:504–512
71. Andersson C, Gislason GH, Jorgensen CH et al (2011) Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pract 94:119–125
72. Andersson C, Olesen JB, Hansen PR et al (2010) Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 53:2546–2553
73. Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM (2011) Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Pharmacoepidemiol Drug Saf 20:785–796
74. Hernan MA, Hernandez-Diaz S, Robins JM (2013) Randomized trials analyzed as observational studies. Ann Intern Med 159:560–562
75. Hernan M, Hernandez-Diaz S (2012) Beyond the intention-to-treat in comparative effectiveness research. Clin Trials 9:48–55
76. Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology, 3rd edn. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia
77. Jorgensen CH, Gislason GH, Andersson C et al (2010) Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention—a retrospective nationwide cohort study. Cardiovasc Diabetol 9:54
78. Schramm TK, Gislason GH, Vaag A et al (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32:1900–1908
79. Robins J (1992) Estimation of the time-dependent accelerated failure time model in the presence of confounding factors. Biometrika 79:321–334
80. Hernan M, Brumback B, Robins J (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11:561–570
81. Robins J, Hernan M, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11:550–560
82. Robins J (1986) A new approach to causal inference in mortality studies with sustained exposure periods—application to control of the healthy worker survivor effect. Math Model 7:1393–1512
83. Walker AM (1991) Observation and inference: an introduction to the methods of epidemiology. Epidemiology Resources Inc., Chestnut Hill
84. Walker AM (1996) Confounding by indication. Epidemiology 7:335–336
85. Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10:577–581
86. Centers for Disease Control and Prevention (2011) National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta
87. Berger AK, Breall JA, Gersh BJ et al (2001) Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly (the Cooperative Cardiovascular Project). Am J Cardiol 87:272–277
88. Smooke S, Horwich TB, Fonarow GC (2005) Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 149:168–174
89. Aronow WS, Ahn C (2001) Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. Am J Cardiol 88:556–557
90. Fisman EZ, Tenenbaum A, Boyko V et al (2001) Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 24:151–158
91. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM (2005) Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111:583–590
92. Arruda-Olson AM, Patch RK 3rd, Leibson CL et al (2009) Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. Mayo Clin Proc 84:28–33
93. Monami M, Balzi D, Lamanna C et al (2007) Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 23:479–484
94. Horsdal HT, Johnsen SP, Sondergaard F et al (2009) Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev 25:515–522
95. Tzoulaki I, Molokhia M, Curcin V et al (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731
96. Weih M, Amberger N, Wegener S, Dirnagl U, Reuter T, Einhaupl K (2001) Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke 32:2029–2032
97. Inzucchi SE, Masoudi FA, Wang Y et al (2005) Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28:1680–1689
98. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298:2634–2643
99. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L (2008) The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 29:166–176
100. Sadikot SM, Mogensen CE (2008) Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract 82:391–395
101. Sillars B, Davis WA, Hirsch IB, Davis TM (2010) Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. Diabetes Obes Metab 12:757–765
102. Stockl KM, Le L, Zhang S, Harada AS (2009) Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications. Pharmacoepidemiol Drug Saf 18:166–174
103. Ramirez SP, Albert JM, Blayney MJ et al (2009) Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol JASN 20:1094–1101
104. Vanasse A, Carpentier AC, Courteau J, Asghari S (2009) Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients. Diab Vasc Dis Res 6:87–93
105. Schneeweiss S, Patrick AR, Brookhart AM et al (2007) Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 45:S131–S142
106. Peduzzi PCJ, Kemper E, Holford TR, Feinstein AR (1996) A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49:1373–1379
107. Cepeda MS, Boston R, Farrar JT, Strom BL (2003) Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 158:280–287
108. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41–55
109. D'Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281
110. Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39:33–38
111. Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083–3107
112. Powers AC (2012) Diabetes mellitus. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J (eds) Harrison's principles of internal medicine, 18th edn. McGraw-Hill, New York
113. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596
114. Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189–1195
115. Nissen S, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471
116. Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S (2011) Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol 173:1404–1413
117. Rassen JA, Schneeweiss S (2012) Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf 21:41–49
118. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart AM (2009) High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20:512–522
119. Stergachis A (1988) Record linkage studies for postmarketing drug surveillance: data quality and validity considerations. Drug Intell Clin Pharmacol 22:157–161
120. McKenzie D, Semradek J, McFarland B, Mullooly J, McCamant L (2000) The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol 53:1248–1257
121. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A (1995) Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 142:1103–1112
122. West SL, Strom BL, Freundlich B, Normand E, Koch G, Savitz DA (1994) Completeness of prescription recording in outpatient medical records from a health maintenance organization. J Clin Epidemiol 47:165–171
123. Kelsey JL, Whittemore AS, Evans AS, Thompson W (1996) Methods in observational epidemiology. Monographs in epidemiology and biostatistics vol. 26, 2nd edn. Oxford University Press, New York, pp 341–361
124. Kiyota Y, Schneeweiss S, Glynn R, Cannuscio C, Avorn J, Solomon D (2004) Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 148:99–104
125. Tirschwell D, Longstreth WJ (2002) Validating administrative data in stroke research. Stroke J Cereb Circ 33:2465–2470
126. Wahl P, Rodgers K, Schneeweiss S et al (2010) Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf 19:596–603
127. Saczynski J, Andrade S, Harrold L et al (2012) A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf 21:129–140
128. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF (2005) Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 43:480–485
129. Hernandez-Diaz S, Adami HO (2010) Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 53:802–808
130. Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35:2665–2673
131. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG (2012) Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55:1607–1618
132. Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H (2012) Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55:1619–1632